Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
Journal Title: Journal of Vaccines & Immunization - Year 2015, Vol 3, Issue 2
Abstract
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardiovascular disease, pulmonary disease, or diabetes mellitus). This analysis is consistent with data suggesting immunocompetent at-risk populations aged ≥50 years produce functional anti-pneumococcal antibody responses to PCV13 comparable to those not at risk. An OPA titer that correlates with protection has not been defined for adults; however, PCV13 elicits generally higher responses than the 23-valent pneumococcal polysaccharide vaccine (PPSV23) one month after vaccination. PCV13 vaccination of immunocompetent at-risk populations likely results in benefits analogous to those without additional risk.
Authors and Affiliations
Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Sundaraiyer V, Gruber WC, Scott DA, Isturiz RE
Keywords
Related Articles
- EP ID EP566654
- DOI 10.14312/2053-1273.2015-2
- Views 40
- Downloads 0
Influenza and pneumococcal vaccination in hospitalized adults with pandemic (H1N1) 2009: Immunization practices and impact on clinical presentation and outcomes
The purpose of this study was to determine vaccination rates against influenza and pneumococcus in a large cohort of adults hospitalized with confirmed influenza A(H1N1) pdm09 infection, and to identify differences in cl...
Home-based vaccination records and hypothetical cost-savings due to avoidance of re-vaccinating children
As national immunization programmes, particularly those in low- and middle-income countries where administrative recording of services received is often absent or sub-optimal, enter a period of rapidly paced change with...
An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine
We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary...
Developing a vaccine for human rhinoviruses
Rhinoviruses (RV’s) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute...
Silk-based microneedle transdermal immunization with EV71 vaccines elicits potent immune responses in mice
Hand, foot, and mouth disease (HFMD), caused by EV71 viral infection, has emerged as a serious public health concern in the Asia-Pacific region. The lack of effective treatment has led to a focus on controlling EV71 epid...